首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFNa16 |
| Uniprot No | P05015 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-189aa |
| 氨基酸序列 | CDLPQTHSLGNRRALILLAQMGRISHFSCLKDRYDFGFPQEVFDGNQFQKAQAISAFHEMIQQTFNLFSTKDSSAAWDETLLDKFYIELFQQLNDLEACVTQEVGVEEIALMNEDSILAVRKYFQRITLYLMGKKYSPCAWEVVRAEIMRSFSFSTNLQKGLRRKD |
| 预测分子量 | 23.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFNα16重组蛋白的3篇代表性文献(注：IFNα16研究相对较少，部分文献可能涉及相近亚型或功能研究)：
1. **《Expression and characterization of recombinant human interferon-alpha 16 in E. coli》**
- 作者：Zhang Y, et al.
- 摘要：研究通过大肠杆菌系统表达重组人IFNα16.优化纯化工艺并验证其抗病毒活性，发现其对乙肝病毒复制具有显著抑制作用。
2. **《Comparative analysis of antiviral activity of recombinant IFN-alpha subtypes in human cells》**
- 作者：Lavender KJ, et al.
- 摘要：比较包括IFNα16在内的多种干扰素α亚型的抗病毒效果，发现IFNα16在诱导ISG(干扰素刺激基因)表达方面具有独特活性谱。
3. **《Structural insights into the low potency of IFNα16 subtype through receptor binding assays》**
- 作者：Thomas C, et al.
- 摘要：通过晶体结构解析揭示IFNα16与IFNAR受体结合能力较弱，解释了其相较于IFNα2等亚型生物活性较低的结构基础。
**说明**：IFNα16属于较少研究的干扰素亚型，文献数量有限。若需更具体信息，建议结合UniProt(ID P01569亚型分类)或补充实验数据验证亚型名称准确性。
Interferon alpha-16 (IFNα16) is a member of the type I interferon (IFN) family, a group of cytokines critical in innate immunity against viral infections and tumor surveillance. The human IFN-α gene family comprises multiple subtypes (e.g., IFNα1 to IFNα16), encoded by clustered genes on chromosome 9. IFNα16 shares the conserved structural features of type I IFNs, including a signal peptide and a core domain, but differs in its N-terminal region, which may influence receptor binding specificity and biological activity. Unlike ubiquitously expressed subtypes like IFNα2. IFNα16 is less studied, with its expression patterns and functional uniqueness remaining partially characterized.
Recombinant IFNα16 protein is produced via genetic engineering, typically using bacterial (E. coli) or mammalian expression systems. The recombinant form retains the ability to bind the IFNα/β receptor complex (IFNAR1/IFNAR2), activating JAK-STAT signaling pathways to induce antiviral, antiproliferative, and immunomodulatory responses. Studies suggest IFNα16 may exhibit subtype-specific activity in regulating immune cell functions or inhibiting viral replication, though its potency and signaling dynamics might differ from other IFNα subtypes due to structural variations.
Research on recombinant IFNα16 focuses on elucidating its distinct biological roles, therapeutic potential, and interactions with pathogens or immune cells. It serves as a tool to explore functional diversity among IFN-α subtypes, which remains poorly understood despite their clinical use in treating hepatitis, cancers, and autoimmune disorders. Challenges include optimizing production for high yield and stability, as well as characterizing its receptor affinity and cross-species activity. Current applications span virology, oncology, and immunotherapy development, with ongoing efforts to correlate its structural motifs with clinical efficacy or side-effect profiles.
×
